Prophase Labs, INC 8-K filings

ProPhase Labs, Inc. has entered into a senior secured convertible loan agreement for $2,085,000, receiving net proceeds of $1,020,000 after fees and reserves.

ProPhase Labs initiates a strategic process for its BE-Smart esophageal cancer test and provides a positive update on its Crown Medical Collections initiative, aiming for significant liquidity.

ProPhase Labs invites investors to a webinar featuring CEO Ted Karkus to discuss its high-growth healthcare portfolio and strategic initiatives.

ProPhase Labs provides an operational update on its Crown Medical Collections initiative, engaging over 250 payors with 50 matters in advanced settlement for legacy COVID-19 testing receivables.

ProPhase Labs' common stock has been approved for uplisting from the Pink Sheets to the OTC market, signaling a move towards greater transparency and investor access.

ProPhase Labs, Inc. has entered into a Stock Purchase Agreement with Generating Alpha Ltd. for an equity line facility providing up to $10 million in equity capital.

ProPhase Labs provided a shareholder update addressing recent stock volatility, significant convertible debt conversions, and its transition to the OTC market, asserting that underlying asset value remains unchanged.

Warren Hirsch has resigned from the Board of Directors of ProPhase Labs, Inc., effective January 5, 2026, with no reported disagreements.

ProPhase Labs, Inc. received a delisting notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, with trading suspension set for January 5, 2026.

ProPhase Labs has signed a non-binding Letter of Intent for a proposed reverse merger with European biotechnology company Advanced Biological Laboratories S.A., which would make ABL the majority owner of the combined entity.

ProPhase Labs, Inc. filed an 8-K to replace a previously filed legal opinion concerning its At-the-Market offering of common stock.

ProPhase Labs, Inc. will effect a 1-for-10 reverse stock split on December 22, 2025, to meet Nasdaq listing requirements and support its reverse merger strategy.

ProPhase Labs, Inc. will effect a 1-for-10 reverse stock split of its common stock to meet Nasdaq listing requirements and support its reverse merger strategy.

ProPhase Labs completed a 1-for-10 reverse stock split to boost its share price and maintain NASDAQ listing compliance.

ProPhase Labs' stockholders approved all six proposals at a Special Meeting, including the ability to acquire digital assets, create digital treasury shares, authorize digital token issuance, and effect stock splits.

ProPhase Labs, Inc. announced it secured an extension of its equipment lease forbearance with Avtech Capital, LLC, establishing a new weekly payment schedule to address past-due amounts.

ProPhase Labs disclosed the unsealing of a False Claims Act lawsuit, denying wrongdoing and stating no material operational impact is expected.

ProPhase Labs reports Q3 2025 financial results, revealing a net loss while pursuing strategic initiatives, including M&A discussions and commercialization of its BE-Smart cancer test.

ProPhase Labs, Inc. has established an At-the-Market Sales Agreement with WestPark Capital, Inc. to sell up to $4.2 million of its common stock.

ProPhase Labs, Inc. engaged ThinkEquity LLC as its exclusive strategic advisor and placement agent for a proposed $6 million private placement and digital asset treasury strategy.

ProPhase Labs stockholders approved a significant increase in authorized common stock to 1 billion shares, new equity incentive plans, and the vesting of warrants for its CEO and an investor.

ProPhase Labs, Inc. has terminated its Common Stock Purchase Agreement with Keystone Capital Partners, LLC, ending an equity line of credit facility without penalty.

ProPhase Labs filed its definitive proxy statement, received SEC clearance, and adjourned its Special Meeting to September 9, 2025, to advance a new crypto treasury strategy and other growth initiatives.

ProPhase Labs announced a significant earnings turnaround in Q2 2025, driven by operational improvements, debt reduction, and strategic initiatives including a new patent and potential $50 million recovery.

ProPhase Labs, Inc. announced the resignation of its Chief Operating Officer and the immediate appointment of Steven M. Plumb as fractional Chief Financial Officer.

ProPhase Labs announced a Special Meeting of Shareholders to vote on increasing authorized shares to 1 billion, aiming to pursue a digital asset treasury strategy and attract industry-leading crypto participants.

ProPhase Labs, Inc. has entered into a private placement agreement to raise $3 million through the issuance of 20% OID Senior Secured Convertible Notes and warrants, aiming to bolster working capital and repay existing debt.

ProPhase Labs, Inc. announced the successful completion of its Annual Meeting of Stockholders, including the election of directors, ratification of auditors, approval of executive compensation, and regaining compliance with Nasdaq listing rules.

ProPhase Labs, Inc. has closed a $3 million private placement of senior secured convertible notes and warrants to fund working capital, repay debt, and advance strategic initiatives including potential liquidity events and crypto strategies.

ProPhase Labs, Inc. announced its Board of Directors has authorized the exploration of a potential reverse merger with a digital asset-focused company and approved a strategic treasury initiative to acquire and hold digital assets, including Bitcoin.